{"id":"W4379338875","doi":"10.1200/jco.2023.41.16_suppl.10016","title":"A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Refractory (planetary science); Interim analysis; CD22; Gastroenterology; Minimal residual disease; Surgery; Chemotherapy; Randomized controlled trial; Leukemia; Lymphoma; CD20","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002448461,0.001676807,0.001380618,0.0004376612,0.0004398081,0.0008461854,0.0009807233,0.001342966,0.007136765],"category_scores_gemma":[0.001324302,0.0005739825,0.001215959,0.0003717276,0.0006598916,0.0006293739,0.0004252947,0.004218876,0.001313588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001188778,"about_ca_system_score_gemma":0.002504365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001477604,"about_ca_topic_score_gemma":0.003349845,"domain_scores_codex":[0.9993976,0.0003345524,0.00002101981,0.00006853303,0.00006122317,0.0001171151],"domain_scores_gemma":[0.9989161,0.0001933399,0.0002264064,0.00009019024,0.00006693498,0.0005070902],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7883596,0.04805661,0.00505274,0.0009869061,0.00135076,0.0002985608,0.0002628103,0.001998983,0.03082806,0.0006510649,0.02149948,0.1006544],"study_design_scores_gemma":[0.857031,0.1287478,0.005439552,0.00005371552,0.0002867592,0.0001838475,0.00002255076,0.0006310271,0.002487056,0.000264297,0.00483501,0.00001736542],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9731627,0.00440848,0.001274258,0.00219317,0.0003144147,0.00753648,0.005725911,0.000241336,0.005143331],"genre_scores_gemma":[0.953021,0.003419765,0.005758734,0.003382284,0.000319206,0.01606222,0.01089835,0.0001278818,0.007010434],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007136765,"threshold_uncertainty_score":0.02387482,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1179596185708861,"score_gpt":0.4957514350111695,"score_spread":0.3777918164402835,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}